beta

CRVS

Corvus Pharmaceuticals, Inc.

Crvs

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

Market Cap: 94.4 Million

Primary Exchange: NASDAQ

Website: http://www.corvuspharma.com

Shares Outstanding: 29.4 Million

Float: 21.1 Million

Dividend: (%)

Beta: 1.4012066801726

Sector: Health Technology

Industry: Pharmaceuticals: Major

Short Interest (Jan 12, 2018): 1.02 Million

Ethical Flags

Animal testing

Longest drawdown: 945 trading days

From: 2017-03-27 To: 2019-11-12

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud